-transparent.png){kind=logo}
129 patients who received a cadaver renal transplant entered a randomised prospective trial of cyclosporin for 3 months with conversion to azathioprine and prednisolone compared with conventional therapy of azathioprine and prednisolone. In the 64 patients who received cyclosporin, actuarial patient survival was 92%, and actuarial graft survival was 72% and 67% at 1 and 4 years after transplantation. Graft survival was significantly better (p less than 0.03) than in the 65 patients who received conventional therapy, in whom actuarial patient survival was 94%, and actuarial graft survival was 59% and 47% at 1 and 4 years. Renal function and other side-effects improved quickly after conversion with the better renal function maintained throughout follow-up. Renal biopsies at 90 days and 1 year in all patients did not show consistent improvement after conversion from cyclosporin in the histological features that might be attributable to cyclosporin toxicity. After conversion, 32% of the patients had acute rejection, generally within 30 days. 1 graft was lost to early acute rejection after conversion and another was lost 3 months later from acute-on-chronic rejection. A total of 8 grafts were lost to chronic rejection in the cyclosporin-treated group and 6 in the conventional group. The improvement in renal function obtained with this protocol of short-term cyclosporin with conversion to azathioprine and prednisolone has to be balanced against the risk of acute rejection and even loss of the graft after conversion.
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
May 2003,
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
March 1987,
Lancet (London, England),
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
January 1985,
Archivum immunologiae et therapiae experimentalis,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
June 2023,
World neurosurgery,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
January 2007,
Annals of oncology : official journal of the European Society for Medical Oncology,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
January 1993,
Ocular immunology and inflammation,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
December 1985,
Clinical orthopaedics and related research,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
November 1993,
Revue medicale de la Suisse romande,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
January 2004,
Japanese heart journal,
P J Morris, and
J R Chapman, and
R D Allen, and
A Ting, and
J F Thompson, and
M S Dunnill, and
R F Wood
February 2004,
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie,
